Tiaa Fsb trimmed its holdings in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 12.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 9,928 shares of the medical research company’s stock after selling 1,394 shares during the period. Tiaa Fsb’s holdings in Edwards Lifesciences were worth $821,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently modified their holdings of the company. Trifecta Capital Advisors LLC acquired a new stake in shares of Edwards Lifesciences in the 4th quarter worth about $28,000. Core Alternative Capital increased its holdings in shares of Edwards Lifesciences by 96.1% in the 1st quarter. Core Alternative Capital now owns 353 shares of the medical research company’s stock worth $29,000 after acquiring an additional 173 shares during the period. Addison Advisors LLC increased its holdings in shares of Edwards Lifesciences by 708.0% in the 4th quarter. Addison Advisors LLC now owns 404 shares of the medical research company’s stock worth $30,000 after acquiring an additional 354 shares during the period. Compass Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences in the 4th quarter worth about $31,000. Finally, MCF Advisors LLC increased its holdings in shares of Edwards Lifesciences by 179.6% in the 1st quarter. MCF Advisors LLC now owns 411 shares of the medical research company’s stock worth $34,000 after acquiring an additional 264 shares during the period. 79.78% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of analysts recently weighed in on EW shares. Truist Financial increased their price objective on shares of Edwards Lifesciences from $97.00 to $101.00 in a report on Thursday, May 18th. Wells Fargo & Company increased their target price on shares of Edwards Lifesciences from $78.00 to $90.00 in a research report on Thursday, April 27th. UBS Group initiated coverage on shares of Edwards Lifesciences in a research report on Tuesday, March 28th. They issued a “neutral” rating and a $84.00 target price for the company. StockNews.com initiated coverage on shares of Edwards Lifesciences in a research report on Thursday, May 18th. They issued a “buy” rating for the company. Finally, Citigroup increased their target price on shares of Edwards Lifesciences from $92.00 to $97.00 and gave the company a “buy” rating in a research report on Monday, April 3rd. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, Edwards Lifesciences presently has an average rating of “Hold” and a consensus price target of $90.00.
Edwards Lifesciences Stock Performance
Edwards Lifesciences (NYSE:EW – Free Report) last announced its earnings results on Wednesday, April 26th. The medical research company reported $0.62 EPS for the quarter, topping the consensus estimate of $0.61 by $0.01. Edwards Lifesciences had a net margin of 27.07% and a return on equity of 25.81%. The company had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.39 billion. During the same period last year, the company posted $0.60 earnings per share. The business’s revenue for the quarter was up 8.8% on a year-over-year basis. On average, equities research analysts expect that Edwards Lifesciences Co. will post 2.55 earnings per share for the current year.
Insiders Place Their Bets
In other news, VP Donald E. Bobo, Jr. sold 6,725 shares of the stock in a transaction that occurred on Thursday, April 6th. The shares were sold at an average price of $83.09, for a total value of $558,780.25. Following the completion of the sale, the vice president now directly owns 62,824 shares of the company’s stock, valued at $5,220,046.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Michael A. Mussallem sold 19,875 shares of the stock in a transaction that occurred on Friday, April 14th. The shares were sold at an average price of $84.20, for a total value of $1,673,475.00. Following the completion of the sale, the chief executive officer now directly owns 60,948 shares of the company’s stock, valued at $5,131,821.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 6,725 shares of the stock in a transaction that occurred on Thursday, April 6th. The stock was sold at an average price of $83.09, for a total transaction of $558,780.25. Following the completion of the sale, the vice president now directly owns 62,824 shares of the company’s stock, valued at $5,220,046.16. The disclosure for this sale can be found here. Insiders sold a total of 208,406 shares of company stock worth $18,200,490 over the last ninety days. 1.29% of the stock is currently owned by company insiders.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.
Recommended Stories
- Five stocks we like better than Edwards Lifesciences
- MarketBeat Week in Review – 6/26 – 6/30
- Tesla: Can Downgrades Make Sense After A 170% Rally?
- Buffett’s Berkshire Increases Stake In Occidental Petroleum (OXY)
- Rally Gains Momentum On Soft PCE Data
- Bank of America, JPMorgan, Goldman Sachs Set For Dividend Growth?
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
